Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?

Karin Cerna Dana Duricova Martin LukasMartin KolarNadezda MachkovaVeronika HrubaKatarina Mitrova Kristyna KubickovaMarta KostrejovaJakub JirsaKristyna KastylovaStepan PeterkaGabriela Vojtechova Milan Lukas

Published in: Crohn's & colitis 360 (2023)

Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
risk assessment
patient reported outcomes
human health